Presentation of the Centre

CRO - Institute for Research, Hospitalization and Health Care (IRCCS) opened in 1984 and accredited by the Italian Ministry of Health in 1990 - is a public, no-profit institute that operates under the authority of the Italian Ministry of Health for the clinical & experimental research functions and under the governance of the Friuli Venezia Giulia Region for patients’ care.

Main Research Activities

The current research activity at CRO is based on five lines which are consistent with the Institute’s objectives, i.e. translational research in oncology and precision medicine, mainly preclinical. The lines are:

• Tumor genetics and biology
• Tumor epidemiology, prevention and health big data
• Lympho-hematologic neoplasias
• Solid tumors

Clinical research is based on mono- and multidisciplinary therapeutic protocols (conservative surgery in breast cancer; combined chemotherapy and radiotherapy in locally advanced lung cancer; interdisciplinary treatment of intestinal and ovarian tumors and soft tissue sarcomas. Experimental research focuses on: gene alterations; neoplastic transformation and progression; mechanisms of cell adhesion and migration; role of growth factors and growth factor receptors in lympho-hematological neoplasias; mechanisms of drug sensitivity and resistance; mechanisms of action of non-genetic cancer risk factors.

Core Facilities

• Pharmacogenomics
• Proteomics
• Flow cytometry
• Biobanking
• Centralized clinical trials office
• Genomics
• Animal Facility
• In vitro and in vivo imaging

Education

Collaborations with the Universities of Trieste, Udine and others allow the presence at CRO of residents in medical oncology and other relevant disciplines and PhD students. Students can find hospitality in the nearby Campus that also hosts educational facilities.

Presentation of the Centre

IRCCS Ospedale Policlinico San Martino (HSM) Comprehensive Cancer Centre (HSMCCC) is the main cancer centre of Regione Liguria. It operates within HSM as a specialised centre for cancer research, treatment, and education. HSMCCC offers dedicated clinical and research spaces and clinical pathways tailored for each patient's need, integrating cutting-edge technology. HSMCCC supports a multidisciplinary and integrated approach among health care professional to provide the best care to cancer people.

Main Research Activities

• Clinical and Translational Studies
• Integration of Oncologic Treatment Modalities
• Evolution of Diagnostic Techniques
• Pathology and Molecular Diagnostics
• Diagnostic and Precision Medicine
• Immunology, Immunotherapy and Cellular Treatment Strategies
• Molecular and Genetic Research
• Prevention and Epidemiology
• Innovative Surgical and Mini-Invasive Diagnostics

Core Facilities

Research and clinical facilities include Robotic surgery rooms, Radiopharmacy, Biological Resources Center, Genomics, Flow Cytometry and Mass Cytometry Laboratory, Proteomics and Mass Spectrometry, Advanced Microscopy lab, Life Science Computational Lab, Animai Facility, Virai Vector Core facility, Research Integrity Office, Technologies Transfer Office, Clinica! Trial Unit Phasel- Cellular therapy.

Education

HSMCCC is affiliated with the Medical School of the University of Genoa, providing many programs in different areas of life sciences related to cancer including residency schools and PhD programs. HSMCCC also welcomes national and international trainees and post-docs.

Presentation of the Centre

The European Institute of Oncology (IEO) is one of the world's leading healthcare facilities specializing in adult cancer treatment. The IEO integrates the various areas related to the fight against cancer such as prevention, diagnosis, treatment, training and education, basic and translational research. The IEO Group includes IEO, Monzino Cardiological Centre and their foundation, Fondazione IEO-Monzino. The strength of the IEO Group comes from the integration of different specialties which combine oncology, cardiology, scientific research and technology transfer.

Main Research Activities

At IEO, a complete integration exists between clinical and research activities in order to translate scientific results into therapy. Basic and translational research takes place at the Department of Experimental Oncology (DEO). IEO has also established various collaborations with the academic world, participating in the university education.
Since its set up, the IEO has contributed to a better understanding of various tumors and has led to new protocols and treatment regimens which have become standard practice both nationally and internationally. The excellence of IEO is reflected also in the IEO innovative organizational model which involves Clinical Programs. Each program brings together all those specialties needed to manage patients throughout the complete clinical pathway, from diagnosis to follow-up.

Presentation of the Centre

The National Cancer Institute of Naples - Fondazione “Giovanni Pascale” (INT – Pascale) is the largest Clinical Care and Research Cancer Center in Southern Italy. It is composed of four buildings in the Main Campus in Naples:

• Main Hospital Building with Operating Theatre (186 in-patient beds);
• Day Hospital and Day Surgery Building (42-day hospital beds);
• Research Building;
• Administrative Building

Main Research Activities

The research activities of the INT- Pascale are financed with intramural funds made available by the Ministry of Health and with competitive grants from public National and International bodies (including EU) as well as from non-profit and profit private bodies The research program is organized in four macro-areas:

• Prevention, one health, quality of life and survivorship
• Immuno-oncology
• Biomarkers and precision oncology
• Diagnostic-therapeutic technology and management innovation.

Core Facilities

Some advances in cancer control:

• Pathology
• Biobank
• Clinical Pathology Laboratory
• Radiology and Interventional Radiology
• Centralized Radiotherapy
• Minimally invasive surgery (2 Robotized “da Vinci” Surgical Systems)
• Pharmacogenomics facility
• Proteomics & Metabolomics facilities
• Animal facility
• Nuclear medicine with Cyclotron and Radiopharmacy
• 4 Phase I facilities (including Nuclear Medicine)
• Drug discovery facility, including in silico, High throughput screening (HTS) and high content screening (HCS) robotic platform for rapid ex vivo drug testing

Education

At INT-Pascale there are four undergraduate programs:

• Two Bachelor of Science in Nursing schools
• Bachelor of Science in Biomedical Laboratory Techniques
• Bachelor of Science in Medical Radiology Techniques

The Director’s Preface

The IRCCS Regina Elena National Cancer Institute (IRE) is the largest Comprehensive Cancer Centre in central Italy, and is renowned for its excellence in the study and treatment of various cancers. IRE's main research objective is the translational management of cancer, which ensures patient-centered care

Description of the Centre and its History

IRE was established in 1933 and was nominated an IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico - Scientific Institute for Research, Hospitalization, and Healthcare) for the first time in 1938 and was very recently reconfirmed the title of IRCCS in June 2024. IRE performs around 10.000 surgeries annually, including 1.300 robotic surgeries. It has more than 1.500 staff members, comprising of researchers, physicians, nurses and administration personnel. It is composed of two departments: the Department of Clinical and Oncological Research and the Department of Research and Advanced Technologies.

Main Research Activities

Every year IRE publishes more than 400 scientific articles in peer-reviewed journals, with approximately 10% of them in journals with an IF > 10 in the last few years. IRE is also greatly involved in clinical trials. In 2023, there were a total of 412 open clinical trials, of which 170 were interventional and 242 observational. In 2020, IRE established seven Translational Research Interest Groups (TRIGs) with the aim to enhance the collaboration between clinical and laboratory investigators on specific research themes. In 2018, the institute also established an Institutional Molecular Tumor Board, the first one in Italy. IRE collaborates with several universities and research centers in Rome as well as on a national and international level. Its research is supported mainly by funds granted from the Italian Ministry of Health, the Italian Ministry of University and Research, AIRC, Lazio Region and EC.

Core Facilities

IRE's Personalized Medicine includes Next-Generation Sequencing (NGS) diagnostics and advanced facilities for performing accurate analyses. The Bioinformatics Group interprets data from various sequencing and epigenomic studies, utilizing High-Performance Computing environments. The Biobank collects, stores, and distributes human biological materials for research. Quite recently, a central facility for Tumor Organoid generation, molecular characterization and drug testing has been established.

Education

Recognized by AGENAS, IRE provides Continuing Medical Education (CME) through residential, field training, and distant learning methodologies.

Presentation of the Centre

The Comprehensive Cancer Center (CC) of the IRCCS Ospedale San Raffaele was formally established in 2021 for

• Promoting synergies and communication between Research and Clinics in Oncology
• Ensuring equal, standardized and high-quality access to cancer patients
• Pursuing the improvement of the outcomes and quality of life of cancer patients

Main Research Activities and Core Facilities

The Centre is promoter and collaborator of national and international clinical, translational and basic cancer researches.

Main Core Facilities are:

Phase-1 clinical Units for early phase studies with accreditation for ATMPs; Biobank, PET and Nuclear Medicine, Clinical Trial Center, Flow cytometry and cell sorting, Omics facilities, Experimental Imaging, Advanced Technology, Animal biochemistry, Animal Histopathology, Preclinical Imaging, Mouse behaviour facility.

Education

Education in oncology is provided by the Faculty of Medicine and Surgery of the Vita-Salute San Raffaele University (UniSR) as part of the San Raffaele Campus. UniSR offers an International Medical Doctor (IMD) Program, post-graduate residency in Medical Oncology and Hematology and a dedicated PhD Program in molecular medicine focused on cancer biology and immunology.

Presentation of the Centre

The Veneto Institute of Oncology (IOV) is a highly specialized research and care provider in Oncology. It specializes in the diagnosis and both standard and experimental treatment of all types of oncologic diseases, including rare and hematologic diseases. Patients with primary, recurrent, and metastatic conditions are managed according to national and international guidelines using the most advanced diagnostic and therapeutic tools. Specific attention is dedicated to end-of-life treatment and patient-centered care, following a multidisciplinary approach. In addition, IOV is an active research player at the international level. Its clinicians/researchers collaborate with the most important European and international cancer organizations and pharmaceutical companies. It is an accredited member of the European Rare Adult Solid Cancers Network (EURACAN). IOV is the clinical hub of the Veneto Regional Oncology Network.

Core Facilities

Inpatient facilities that comprise oncology wards including end-of-life dedicated unit Advanced radiological diagnostics facility High-tech and robotic surgical facilities High-tech Radiation therapy. Molecular Oncology laboratories evaluating circulating tumor cells and somatic genomic testing for both diagnostic and research purposes. Animal facility.

Main Research Activities

Fundamental and translational research; Tumor immunology; Clinical and translational research and innovative therapies; New logistic care models: Diagnostic, monitoring, and therapeutic pathways with related performance indicators.

Education

The Institute is an official training provider recognized by the Veneto Region. It offers regular training opportunities to the clinical staff and researchers. In collaboration with the Padova University regularly hosts clinicians engaged in residency programs in oncology and PhD students graduating from PhD programs in the Oncology area.

Presentation of the Centre

The Institute in Advanced Technologies and Care Models in Oncology of Reggio Emilia, embedded in the Local Health Authority of Reggio Emilia, has been recognized by the Ministry of Health since 2011 as one of the National Research Cancer Hospitals. The Institute is committed to the prevention, diagnosis, treatment and rehabilitation of oncological patients. The multidisciplinary approach is the main driver for improving the quality of healthcare.

Main Research Activities

The Institute develops research activities of international standing in the field of oncology and onco-hematology, throughout the whole patient's pathway: from screening to diagnostics, from research on drugs and innovative treatments to research on supportive and end-of-life therapies. The Institute relies on the contribution of approximately 200 researchers, in particular doctors, biologists, nurses and other healthcare professionals who combine research activity with clinical practice. More than 50 are young, full-time researchers: they are mostly biologists, who develop molecular research on different types of tumors, in particular breast, lung, colon, thyroid, lymphomas, mesothelioma, melanoma, etc. Other researchers are engaged in oncological rehabilitation, psychological support for patients and families, and palliative care.

Core Facilities

Care activities are guaranteed by the Oncology and Advanced Technologies Department and by the provincial Oncology Network. Most of the disciplines and professionals involved in the oncology patient pathway are concentrated in the CORE – Oncology and Hematology Centre of Reggio Emilia, a 16,000 square meters pavilion that includes 125 of the Institute's 190 total beds.

Education

In recent years, innovative educational paths have been developed on oncological medicine, palliative care, physician-patient communication, ethics and methodology in research, healthcare management. The Institute also promotes the training of new researchers and their integration into the research and clinical facilities through the doctoral program.

Presentation of the Centre

The Institute of Candiolo is a specialized center for cancer treatment and research, recognized as a scientific research hospital by the Italian Ministry of Health since 2013. The Institute’s mission is to make a significant contribution in cure and research in cancer care, through a multidisciplinary approach, teams of specialists with consolidated experience and expertise and close links between research and clinical units, facilitating rapid transfer of research results into clinical practice.

Main Research Activities

The Institute’s research activities cover a broad spectrum of activities focused on: (i) translational, preclinical and clinical cancer research (profit and no profit trials, phase I-IV); ii) promoting the rapid translation of research findings into clinical practice; (iii) developing and implementing the latest diagnostic and therapeutic procedures using state-of-the-art technologies; (iv) contributing to the early diagnosis and prevention of cancer by identifying underlying genetic or environmental factors.

Core Facilities

• Oncogenomics
• Single cells
• Oncology Imaging
• Flow Cytometry
• Xenopatients
• Experimental Pathology
• Cell Culture
• Gene Transfer Technology
• Clinical Research Unit

Education

The Institute has a framework agreement with the University of Torino and is host to several medical faculty professionals.

Presentation of the Centre

The 'Giovanni Paolo II' Tumour Institute, housed in the historic 'Domenico Cotugno' hospital building, has been an IRCCS since 1985, specialising in oncology. Accredited as an OECI Clinical Cancer Centre in 2015, it focuses on cancer diagnosis, treatment, research, and humanisation of care. The Institute prioritises translational research to improve therapies, integrating clinical and basic research, and is committed to excellence in prevention, diagnosis, and rehabilitation.

Main Research Activities

Research includes clinical and translational fields. Clinical research focuses on active studies involving physicians and biologists, while translational research covers omics analyses (genomics, proteomics, radiomics) on liquid biopsies, leveraging AI to study tumour biology and identify biomarkers, neoantigens, and drug targets. Collaborations in nanotechnology will support new drug formulations. Pharmacological screenings using organoids and tumor fragments will explore tumour microenvironment roles in therapy response.

Core Facilities

The Institute is developing a research infrastructure with 8 core facilities: 1) Tumour Biology and Molecular Therapies; 2) Biomarkers and Molecular Targets; 3) Cancer Immunology and Immunotherapy; 4) Omic Sciences; 5) Nanotechnology; 6) Oncological Virology; 7) Oncological Haematology and 8) the Laboratory of Bioinformatics and.

Education

Training is essential for enhancing healthcare professionals' skills and improving services. The Institute offers educational activities for medical, nursing, and technical staff to improve care quality. Continuous Education programs focus on oncology expertise, also engaging General Practitioners for patient care continuity. In collaboration with the University of Bari, the Institute provides training for medical students and graduate researchers. Starting in 2024, a Nursing Degree branch will be offered at the Institute.

Presentation of the Centre

The IRCCS-CROB, Referral Cancer Centre of Basilicata is an autonomous, public, no-profit Institute for Cancer Research and Care (IRCCS). It was recognized by the Italian Ministry of Health and by the Regional Government of Basilicata in 2008 after a starting-up phase shared with the Istituto Nazionale Tumori in Milan. The Institute has two clinical departments (Onco-Haematology and General/Women Surgery) that manage adult solid tumours and haematological malignancies. One additional diagnostic and therapeutic department that includes Radiotherapy, Nuclear Medicine, Laboratory, Radiology/Diagnostic Imaging and Pathological Anatomy. Nephrology, Psycho-oncology and Cardio-oncology services are also available. The Institute coordinates the Regional Cancer Registry and the Screenings for breast, cervix and intestinal cancers and it holds useful relationships with several Universities and other Cancer Centres.

Main Research Activities

According to the institutional research plan, the scientific objectives pursued are:

• new tailored treatments based on molecular traits of tumours (precision medicine)
• novel therapeutic targets and prognostic biomarkers
• innovation in high technologies (radiology, nuclear medicine and radiotherapy), including procedures for monitoring environmental professional risks tumour epidemiology, preventive/predictive medicine, cancer patients’ quality of life and survivorship.

Core Facilities

• Hematopoietic stem cell transplantation
• Thoracic, abdominal, breast, urologic, gynaecologic and plastic/reconstructive specialised surgeries
• Conformational, brachi- and intra-operative radiotherapy (n. 3 linear accelerators)
• Metabolic and radioligand therapies
• Pain therapy (vertebro/kypho-plasty)
• Palliative and Intermediate/Interdisciplinary cares (hospice included)
• Video-mediastinal thoracoscopy 3D
• 3-Tesla RMN with laser-guided system for micro-biopsies
• PET-TC (novel tracers, volumetric evaluation of neoplastic metabolism)
• Bio-banking
• NextSeq 550dx Illumina and Ion GeneStudio S5 next-generation sequencing platforms
• Liquid biopsy (circulating tumor cells)
• Laparoscopic radical prostatectomy 3D and robotic prostate surgery

Presentation of the Centre

The Institute, founded in 1933 by San Giovanni Calabria, is a religious, public entity with a non-profit, private administration. It is accredited by the Regional Health System (Veneto Region) and operate within the national public network. In 2018, it was recognized by the Ministry of Health as an Institute of Recovery and Cure with a Scientific Focus (IRCCS). It collaborates with several Italian Universities for clinical training, teaching and research. In the Institute there are all the main specialties in the medical, surgical, intensive care, maternal-infant and rehabilitation areas.

Main Research Activities

The Institute is engaged in translational and clinical research. The Hospital is a Phase I Centre authorized by Italian Pharmaceutical Agency (AIFA) for conducting Phase I oncological trials. Main important areas of research are: breast cancer, lung cancer, colorectal cancer, prostate cancer, hepatocarcinoma, brain metastasis and oligometastatic diseases. The personalised therapies, the psychosocial interventions in oncological patients and the management of cancer survivors are other areas of research interest.

Core Facilities

Anatomical pathology and Molecular biology, Radiotherapy (n. 3 linear accelerators and n.1 Magnetic Resonance Linear Accelerator - MR Linac), Nuclear Medicine (n. 2 PET/TC) with Radiometabolic Therapy, Cyclotron and Radiopharmacy, Radiology, Analysis Laboratory and Transfusion Medicine, Antiblastic Drug Unit, Clinical Research Unit, Oncogenetic service, Pain therapy and Palliative care Center. There are also thoracic, abdominal, breast, urologic, gynecologic, plastic/reconstructive and head and neck specialised surgeries, minimally invasive surgery (toracoscopy, laparoscopy, robotic surgery).

Education

The Institute is recognised as official provider of the Continuing Medical Education (CME) and collaborates with several Universities both for hosting PhDs and Specialization Schools of medical, surgical and diagnostic area, and for training students of other healthcare professions (nurses, technicians in radiology, physiotherapists…). An agreement has been signed with the University of Verona for which the Institute is a training site for students in medical degree programs.

Presentation of the Centre

ASST Spedali Civili di Brescia (ASST Brescia, founded in 1427), is one of the largest hospitals in Europe with up to 7000 employees. It is a public general hospital, affiliated with the University of Brescia Medical School, and accredited by Regional Health System of Regione Lombardia. It is structured with a Main Campus, located in Brescia, two Satellite Hospitals, and Health Districts devoted to territorial medical care.

Main Research Activities

Translational research studies, related to both solid tumors and hematologic malignancies, are being conducted, focusing on the interaction of the tumor clone and the surrounding microenvironment, development of non-invasive techniques for early tumor detection, clonal evolution, impact of anti-neoplastic drugs on bone and body composition, pre-clinical novel drug and radiation/drug interaction validation, to cite a few. The research mentioned above is the result of ASST Brescia sponsored studies, funded by national and international/EU competitive calls. ASST Brescia has participated to a total of n. 1.971 clinical trials (2019-2023). Dedicated Phase I Units allow pediatric and adult patients to be enrolled in phase I studies. ASST Brescia has been selected as Member the European Reference Networks: EuroBloodNet, EURACAN.

Core Facilities

• Medical Oncology, Pediatric Oncology, Radiation Oncology, Robotic Surgery, Surgery
• Radiology Imaging, Nuclear Medicine
• Palliative care
• Central Pharmacy
• IT Service
• Phase I Unit
• Next generation flow cytometry
• DNA sequencing
• Mass spectrometry
• Molecular pathology
• Clinical Trial Center/Grant Office
• Zebrafish and in vivo animal facility
• Confocal imaging

Education

ASST-BS is affiliated with the University of Brescia Medical School, thus hosting MD students, Residents, Master and PhD students A large portfolio of education and training programs at a post graduated level is offered to health care professionals, including biologists, lab technicians, MDs, nurses , pharmacists, radiation therapy and radiology technologists. National programs for Continuous Medical Education are constantly activated

Presentation of the Centre

The IRST Cancer Institute in Romagna, Italy, founded in 2007 by Prof. Dino Amadori, is a leading centre for cancer research and treatment. Renowned for its innovative approaches and clinical programs, IRST specializes in preclinical research and education, advancing the understanding and treatment of cancer. IRST offers a range of complex clinical services, including Radiometabolic Therapy, Radiotherapy, Advanced Medicinal Products (Somatic Cells and Gene Therapies), and Immunotherapy. Its Precision Medicine Programs tailor treatments to patients' tumors’ molecular characteristics. IRST collaborates with public Health Authorities, the University of Bologna, and the Istituto Oncologico Romagnolo (IOR), integrating into Italy’s National Health Service. It leads the Comprehensive Cancer Care Network with AUSL Romagna to enhance cancer care regionally.

Main Research Activities

Key research areas include:

• Advanced Biomolecular Diagnostics: Enhancing personalized treatment strategies.
• Appropriateness and Outcomes: Optimizing diagnostic-therapeutic pathways.
• Innovative Therapies: Conducting trials and developing novel therapeutic approaches.
• Precision Medicine: Studying genetic and molecular mechanisms for personalized treatment.
• Genetics and Environment: Exploring tumor progression and environmental interactions.

Research Infrastructure and Core Facilities

The institute boasts a comprehensive research infrastructure essential for promoting, conducting, and evaluating cancer care, serving also as a Contract Research Organization (CRO) for external studies. Key facilities include:

• Biosciences and Radiobiology Laboratories
• Flow Cytometry and DNA Sequencing Facilities
• Cell Factory (Somatic Cell Therapy Laboratory)
• Immuno-gene Therapy and Research Factory
• Biological Resource Center and Biobank
• Radiopharmaceutical Production and Antiblastics Laboratories
• Medical Physics Laboratory and IT Services
• Epidemiology and Cancer Registry Unit
• Outcome Research and Data Unit
• Biostatistics, and Clinical Trials Unit
• Research and Innovation Unit

Clinical and Support Services

• Radiometabolic Medicine
• Advanced Imaging 
• Integrative medicine
• Rare tumors and Osteoncology Center
• Genetic Counseling

Education

Since July 2024, a University-directed Medical Oncology Unit (University of Bologna) has been created at IRCCS IRST

Presentation of the Centre

The Fondazione Policlinico Universitario Agostino Gemelli IRCCS (FPG-IRCCS) - the largest academic hospital in Italy - dedicates its mission to all diseases with a special focus on oncology, as 60% of admitted patients are affected by cancer. Over the years, it has developed services of care, diagnosis, treatment, and rehabilitation with a multidisciplinary patient-oriented approach through continuous innovation in research and practice. The FPG-IRCCS is a member of the Italian network of Cancer Institutes (Alliance Against Cancer) and is recognized by the Italian Ministry of Health as “research hospital” for “Personalized Medicine” and “Innovative Biomedical Technologies”

Main Research Activities and Facilities

The FPG-IRCCS is involved in basic, translational and clinical research. Its special focus is on molecular disease determinants, biomarkers for treatment response prediction, development of novel and technological cancer diagnosis and treatment approaches, and continuum of care in all phases of illness from diagnosis to the end of life. These research areas are empowered by a large facility dedicated to bioinformatics and AI aimed at improving imaging diagnostics and treatment, a Clinical Trial Center which coordinates the design and conduct of clinical studies and the “Gemelli Science and Technology Park” (G-STeP), a network of 20 Research Core Facilities equipped with state-of-the art technologies to support all phases of scientific research projects.

Education

The FPG-IRCCS is an academic hospital closely collaborating with the Medical School of the Università Cattolica del Sacro Cuore, present on the same campus, which hosts MD degree students, Residency schools, Master and PhD programs.

Presentation of the Centre

The Institute has been studying skin cancers since 1926 and is involved in clinical and translational activity for the prevention and treatment of melanoma, nonmelanoma skin cancers and cutaneous lymphomas. It is attended by 25,000 patients annually, with about 500 new melanoma diagnoses per year.
The Dermato-Oncology Unit (DOU) focuses on the prevention, diagnosis and follow-up and the Plastic Surgery Unit (PRS) is in charge of demolitive and reconstructive surgical treatment of skin cancers.

Main Research Activities

DOU is regional referral center for rare diseases including familial/multiple melanoma and Gorlin Goltz syndrome. It has a focus on noninvasive diagnostic imaging for screening and follow-up of skin cancers as well as on medical treatment of advanced tumors. PRS is part of the European Reference Network, actively participating in the EURACAN project for the diagnosis, treatment and research of adult solid Rare Tumors G9, such as Merkel cell carcinoma, and contributing to drafting of guidelines. It is reference center for the surgical treatment of melanoma and sentinel lymph node and has recognized expertise in electrochemotherapy for selected cases of advanced skin tumors or cutaneous metastases. Both Units actively participate to weekly disease management team meetings for melanoma and nonmelanoma skin cancers.

Core Facilities

Noninvasive diagnostic techniques such as dermatoscopy, confocal microscopy, and innovative instruments such as 3D whole body imaging.

Education

It is part of the training network of the Dermatology and Plastic, Reconstructive and Aesthetic Surgery Residency Program of the Sapienza University of Rome and contributes to the surgical and scientific training of residents.